Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion announced that researchers will present late-breaking data from a Phase 1/2 dose-escalating study of ALXN1210, the Company’s highly innovative longer-acting C5 antibody, in patients with PNH.
Source: BusinessWire-Primary

Researchers to Present Late-Breaking Data on ALXN1210 in Patients with PNH at EHA Annual Congress